Top Computational Biology Companies

Given the presence of multiple significant competitors, the computational biology market is predicted to become extremely competitive in the near future. Mid-size to smaller businesses are expanding their market presence by releasing new products with lower prices as a result of rising technical breakthroughs and product innovations. Major companies in the market are concentrated on developing new items to extend their product portfolio as well as on implementing collaborative methods to increase their market share. For instance, Genedata, AG released Genedata Imagence 2.0, the most recent iteration of its corporate software for high-content screening (HCS) image analysis, in May 2020.

Top Players in the Computational Biology Market

• DNAnexus, Inc. 
• Illumina, Inc. 
• Thermo Fisher Scientific, Inc. 
• Schrodinger, Inc. 
• Compugen 
• Aganitha AI Inc. 
• Genedata AG 
• QIAGEN 
• Simulations Plus, Inc. 
• Fios Genomics 
• Certara 
• Chemical Computing Group ULC 
• Dassault Systèmes 
• Genedata AG 
• Insilico Biotechnology AG 

Computational Biology Market Recent Development

• In April 2022, Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that the company granted non-statutory stock options to purchase an aggregate of 101,715 shares of the company's common stock to 30 newly hired employees, including six freshly hired employees based in India and one newly hired employee based in Japan.
• In May 2022, Genedata, the leading supplier of enterprise software solutions for biopharmaceutical Research and Development, announced that Ajinomoto, a multinational provider to the biopharmaceutical industry of cell culture media and development and manufacturing services (CDMO), has implemented Genedata Bioprocess® to digitalize and automate their R&D and manufacturing operations in Japan and Korea.
• In May 2021 Certara, Inc., the world leader in biosimulation, has released new versions of its Quantitative Systems Pharmacology (QSP) Simulators for Immunogenicity (IG) and Immuno-oncology (IO) to aid in the development of biologics and cancer treatments.
• In April 2021, Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, announced the successful completion of Phase 1 clinical trial for its lead compound PLG0206, a potent, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections (PJI).
• In March 2021, Compugen Ltd., a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, has published a review article titled "Therapeutic Targeting of Checkpoint Receptors within the DNAM-1 Axis," which looks at the biology and therapeutic relevance of the DNAM-1 axis in cancer immunotherapy.
• In January 2021, AsclepiX Therapeutics Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and oncologic diseases, announced that the first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with Diabetic Macular Edema (DME).